Axomadol - Grunenthal

Drug Profile

Axomadol - Grunenthal

Alternative Names: EN3324; GRT-151; GRT0151Y

Latest Information Update: 14 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Grunenthal
  • Class Analgesics; Cyclohexanes; Phenyl ethers
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pain; Postoperative pain
  • Discontinued Neuropathic pain

Most Recent Events

  • 14 Aug 2015 Phase-II development for Pain is ongoing in Europe
  • 26 Mar 2012 Axomadol is still in phase IIb development for chronic Pain & chronic Neuropathic pain
  • 17 Aug 2011 Axomadol is no longer licensed to Endo Pharmaceuticals in the US and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top